ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,942.47
1.26%
US Tech 100
20,762.73
1.73%
Dow Jones
42,732.13
0.80%
Brent Oil
76.495
0.00%
Bitcoin
98,485.49
0.28%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. IGM Biosciences Inc (IGMS) Quote

IGM Biosciences Inc

IGM Biosciences Inc (IGMS)

NASDAQ
6.56
0.35
(5.64%)
Closed January 05 4:00PM
Delayed by 15 minutes
6.70
0.14
(2.13%)
After Hours: 7:10PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
6.70
Bid
6.58
Ask
13.98
Volume
337,952
6.21 Day's Range 7.02
5.79 52 Week Range 22.50
Market Cap
398.41M
Previous Close
6.21
Open
6.28
Last Trade
7
@
7.03
Last Trade Time
Financial Volume
$ 2,231,533
VWAP
6.6031
Average Volume (3m)
234,523
Shares Outstanding
59,464,181
Dividend Yield
-
PE Ratio
-1.59
Earnings Per Share (EPS)
-4.14
Revenue
2.13M
Net Profit
-246.42M

About IGM Biosciences Inc

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking ago... IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.igmbio.com
Headquarters
Dover, Delaware, USA
Founded
-
IGM Biosciences Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IGMS. The last closing price for IGM Biosciences was $6.21. Over the last year, IGM Biosciences shares have traded in a share price range of $ 5.79 to $ 22.50.

IGM Biosciences currently has 59,464,181 shares outstanding. The market capitalization of IGM Biosciences is $369.27 million. IGM Biosciences has a price to earnings ratio (PE ratio) of -1.59.

Ask ADVFN Intelligence (AI)

IGMS Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities

January 03 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

January 03 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

January 03 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

January 02 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 18 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 18 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 18 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

December 18 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

December 16 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

December 16 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.162.446483180436.546.775.793039056.16747697CS
4-3.3-331010.85.792387167.20117558CS
12-7.19-51.763858891313.8920.355.7923452311.05249925CS
260.233.554868624426.4722.55.7929088112.091583CS
52-1.87-21.82030338398.5722.55.7929692611.24832573CS
156-23.03-77.463841237829.7335.983.8135338616.51905379CS
260-28.32-80.868075385535.02127.113.8128256029.18342635CS

IGMS - Frequently Asked Questions (FAQ)

What is the current IGM Biosciences share price?
The current share price of IGM Biosciences is $ 6.70
How many IGM Biosciences shares are in issue?
IGM Biosciences has 59,464,181 shares in issue
What is the market cap of IGM Biosciences?
The market capitalisation of IGM Biosciences is USD 369.27M
What is the 1 year trading range for IGM Biosciences share price?
IGM Biosciences has traded in the range of $ 5.79 to $ 22.50 during the past year
What is the PE ratio of IGM Biosciences?
The price to earnings ratio of IGM Biosciences is -1.59
What is the cash to sales ratio of IGM Biosciences?
The cash to sales ratio of IGM Biosciences is 183.52
What is the reporting currency for IGM Biosciences?
IGM Biosciences reports financial results in USD
What is the latest annual turnover for IGM Biosciences?
The latest annual turnover of IGM Biosciences is USD 2.13M
What is the latest annual profit for IGM Biosciences?
The latest annual profit of IGM Biosciences is USD -246.42M
What is the registered address of IGM Biosciences?
The registered address for IGM Biosciences is CORPORATION TRUST CENTER, 1209 ORANGE ST, DOVER, DELAWARE, 19901
What is the IGM Biosciences website address?
The website address for IGM Biosciences is www.igmbio.com
Which industry sector does IGM Biosciences operate in?
IGM Biosciences operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
FCUVFocus Universal Inc
$ 0.9499
(174.93%)
260.93M
NITON2OFF Inc
$ 2.6306
(145.85%)
358.28M
CRNCCerence Inc
$ 19.33
(143.76%)
161.8M
KITTNauticus Robotics Inc
$ 3.8249
(140.56%)
104.8M
ACONAclarion Inc
$ 0.2984
(110.14%)
305.64M
HWHHWH International Inc
$ 0.4621
(-28.80%)
7.43M
SMSTDefiance Daily Target 2x Short MSTR ETF
$ 5.69
(-26.30%)
24.77M
RAINRain Enhancement Technologies Holdco Inc
$ 5.59
(-23.42%)
161.15k
PTLEPTL Ltd
$ 9.35
(-23.30%)
1.04M
NXUNXU Inc
$ 0.725868
(-22.78%)
7.59M
NITON2OFF Inc
$ 2.6306
(145.85%)
358.28M
TGLTreasure Global Inc
$ 0.382
(101.58%)
337.5M
ACONAclarion Inc
$ 0.2984
(110.14%)
305.64M
FCUVFocus Universal Inc
$ 0.9499
(174.93%)
260.93M
NVDANVIDIA Corporation
$ 144.47
(4.45%)
230.01M

IGMS Discussion

View Posts
Monksdream Monksdream 6 months ago
IGMS under $10
👍️0
Monksdream Monksdream 8 months ago
IGMS under $10
👍️0
crudeoil24 crudeoil24 3 years ago
Truist Reiterates Buy Rating, $80 Price Target.
👍️0
crudeoil24 crudeoil24 3 years ago
Let's see if IGMS gets FDA phase I,II,III, approvals . Sanofi believes it'll happen.
👍️0
crudeoil24 crudeoil24 3 years ago
14M float!
👍️0
crudeoil24 crudeoil24 3 years ago
Tons of cash going forward > IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell $200.0 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, non-voting common stock, in an underwritten public offering. In addition, IGM intends to grant the underwriters a 30-day option to purchase up to an additional $30.0 million of shares at the public offering price, less underwriting discounts and commissions. All of the securities offered in the offering will be sold by IGM. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
J.P. Morgan, BofA Securities, Stifel, and Guggenheim Securities are acting as joint book-running managers for the offering.
👍️0
TheFinalCD TheFinalCD 3 years ago
https://ih.advfn.com/stock-market/NASDAQ/igm-biosciences-IGMS/stock-news/87682546/igm-announces-proposed-public-offering

https://www.wsgr.com/print/v2/content/185066/Firm-Advises-IGM-Biosciences%2C-Inc.-on-%24230-Million-Public-Offering.pdf
👍️0

Your Recent History

NASDAQ
IGMS
IGM Biosciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads